ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research

Sep 22, 2026

Competitive National Eye Institute funding provides external validation of ClearSight's proposed scientific program and supports a one-year investigation of a preservative-free ophthalmic formulation in acute infectious conjunctivitis and epidemic keratoconjunctivitis.

DALLAS - Sept. 22, 2026 - PRLog -- ClearSight Therapeutics, Inc. Receives NIH SBIR Phase I Award for Research in Acute Infectious Conjunctivitis and EKC

Competitive federal award provides external scientific validation of the proposed research program and funds a disciplined path to new evidence

DALLAS, September 22nd, 2026 - ClearSight Therapeutics, Inc., a Dallas-based eye-care company, today announced that it has received a $306,852 Small Business Innovation Research Phase I award from the National Eye Institute, part of the National Institutes of Health. The competitive award marks a major scientific milestone for ClearSight and supports a one-year investigational research program involving a preservative-free ophthalmic formulation in acute infectious conjunctivitis and epidemic keratoconjunctivitis.

The project, award number R43EY039140, runs from September 15, 2026 through August 31, 2027. ClearSight Chief Scientific Officer Nuria Jimenez, PhD, PMP, will serve as principal investigator. The Notice of Award identifies the project as research and development and states that it does not support an NIH-defined clinical trial.

Why this award matters

NIH funding decisions follow rigorous peer review of scientific and technical merit and a second-level assessment of mission relevance. Reviewers consider the importance of the proposed research, the rigor and feasibility of the approach, and whether the investigators and organization have the expertise and resources to carry out the work. For ClearSight, the award provides meaningful external validation of the proposed scientific program and creates an accountable path for turning a promising research premise into credible evidence. It does not predetermine the results; it makes the disciplined work to generate those results possible.

"This award is a defining milestone for ClearSight. Following competitive review of the scientific and technical merit of our proposed work, NIH support gives us both meaningful external validation and non-dilutive capital to build the evidence base with rigor. It is a powerful vote of confidence in the importance of the question, the strength of the research plan, and our team's ability to execute."

Patrick Smale, Co-founder and Chief Executive Officer

"The questions at the center of this program matter to patients, clinicians, and the broader eye-care community. NIH support gives us the opportunity to investigate them with the rigor they deserve, generate credible data, and let the evidence guide what comes next. I am proud to lead this work alongside our team and collaborators."

Nuria Jimenez, PhD, PMP, Chief Scientific Officer and Principal Investigator

"I am excited and grateful for this initial support from the National Eye Institute, which represents an important step in advancing our innovation toward clinical development. This funding will enable us to generate the rigorous data needed to further validate the technology and its potential to address important unmet needs in topical ocular therapy. As a co-inventor and drug developer, I am particularly encouraged by the opportunity to translate this innovation into a product where patient safety, efficacy, and meaningful clinical benefit remain our highest priorities."

Suchismita Acharya, PhD, Co-Founder, Co-Inventor and Board Member

The SBIR program supports research and development by eligible small businesses. Beyond providing non-dilutive capital, the award gives ClearSight a structured milestone period through August 2027 and an accountable framework for translating a scientific premise into data. The work will proceed under a defined research plan, milestones, and federal reporting obligations.

Important regulatory context

ClearSight's NIH-funded research program will study preservative-free ophthalmic formulation in acute infectious conjunctivitis and EKC. This investigational research is separate from the labeled uses of any OTC lubricant eye drop marketed under M018 and does not establish safety, efficacy, or regulatory approval for treating either condition.

About ClearSight Therapeutics


ClearSight Therapeutics is a Dallas-based eye-care company founded in 2023 by industry veterans to develop accessible solutions for common ocular conditions. The company maintains distinct commercial and research programs, including OTC lubricant development under applicable monograph labeling and separately described investigational research. Learn more at clearsighttx.com.

NIH funding acknowledgment

Research reported in this release is supported by the National Eye Institute of the National Institutes of Health under Award Number R43EY039140. A total of $306,852, or 100% of the project, is financed with federal funds. A total of $0, or 0%, is financed with non-governmental funds. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Media contact

Patrick Smale
Co-founder & CEO
ClearSight Therapeutics
[email protected]
972-983-7761

Contact
Patrick Smale
***@clearsighttx.com

Photos: (Click photo to enlarge)




Source: ClearSight Therapeutics, Inc.

Read Full Story - ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research | More news from this source

Press release distribution by PRLog

More News

European pharma chiefs warn region risks losing ground to America, China
Sep 22, 2026
European pharma chiefs warn region risks losing ground to America, China

Drugmakers for months have been warning they could curtail investments and delay the release of new medications in Europe, widening a disparity in access with the US, unless the region's healthcare systems agree to boost spending.

Afghan cyclist Fariba Hashimi who disguised herself as man wins Asian Games silver
Sep 22, 2026
Afghan cyclist Fariba Hashimi who disguised herself as man wins Asian Games silver

Afghan cyclist Fariba Hashimi won a silver medal in the women's road race at the Asian Games near Nagoya, Japan, after overcoming restrictions on women in Afghanistan and leaving the country following the Taliban's return to power in 2021. Hashimi, who once trained disguised as a man, said she hoped her medal would inspire Afghan women and future generations to pursue their dreams without fear.

Iran is waiting to see how I do in mid-term election: Trump
Sep 22, 2026
Iran is waiting to see how I do in mid-term election: Trump

Trump called for the complete economic isolation of Iran in his UN speech, while saying he expected a deal with Tehran after the November midterm elections. Iran said it could reopen the Strait of Hormuz within seven days if US military pressure and the blockade on Iranian ports were eased. Trump also described Cuba as a failed state.

UK to provide Saudi Arabia defensive air-refuelling support against Houthis
Sep 22, 2026
UK to provide Saudi Arabia defensive air-refuelling support against Houthis

The UK has decided to assist Saudi Arabia's military by providing defensive air-to-air refueling support. This agreement follows a request made by Saudi Arabia to enhance their operational capabilities against the Houthi militants. Prime Minister Andy Burnham confirmed that this military help would be the first of its kind from a foreign country. Saudi Arabia has also sought similar support from the Americans to bolster their defenses.

US midterm elections 2026: A new Congress could change Trump's legislative agenda; what house control means for Washington
Sep 22, 2026
US midterm elections 2026: A new Congress could change Trump's legislative agenda; what house control means for Washington

US midterm elections 2026: Forecasts suggest that Democrats could clinch around 226 seats in the House during the 2026 midterm elections, while the Senate election is shaping up to be a tightly contested affair. This period will be pivotal for Congress as it navigates funding the government and raising the debt ceiling for President Trump.

'Inflated medicine prices are daylight robbery': SC pulls up pharma companies over huge MRP-PTR gap
Sep 22, 2026
'Inflated medicine prices are daylight robbery': SC pulls up pharma companies over huge MRP-PTR gap

Supreme Court on Tuesday questioned the wide gap between the price to retailer and MRP of some cancer medicines, calling inflated pricing a serious issue for patients and taxpayers. The bench said such disparities could lead to excessive costs under government health schemes and sought greater scrutiny of medicine pricing. The court was hearing a petition on generic prescriptions and price controls.

'Inflated medicine prices are daylight robbery': SC pulls up pharma companies over huge MRP-PTR gap
Sep 22, 2026
'Inflated medicine prices are daylight robbery': SC pulls up pharma companies over huge MRP-PTR gap

Supreme Court on Tuesday questioned the wide gap between the price to retailer and MRP of some cancer medicines, calling inflated pricing a serious issue for patients and taxpayers. The bench said such disparities could lead to excessive costs under government health schemes and sought greater scrutiny of medicine pricing. The court was hearing a petition on generic prescriptions and price controls.

Maharashtra drought deepens, crop output crisis mounts
Sep 22, 2026
Maharashtra drought deepens, crop output crisis mounts

State agriculture minister Dattatray Bharane has confirmed a large contraction in the production of cotton and soybean, while the agriculture department has initiated an early crop assessment to calculate compensation as farmers are removing wilted crops from fields.

DNA reveals four gentoo penguin species instead of one after more than 100 years. Scientists now fear some island populations could lose their homes to global warming
Sep 22, 2026
DNA reveals four gentoo penguin species instead of one after more than 100 years. Scientists now fear some island populations could lose their homes to global warming

New genomic research has resolved a century-old debate over gentoo penguins, revealing four distinct species rather than one with several subspecies. The newly recognised Kerguelen gentoo lives on remote islands in the Southern Indian Ocean. Scientists warn that warming temperatures could shrink habitats for several island populations, making conservation increasingly important.

Look beyond premiumisation: FM Nirmala Sitharaman to India Inc
Sep 22, 2026
Look beyond premiumisation: FM Nirmala Sitharaman to India Inc

Sitharaman made a strong pitch for better-governed family businesses and greater corporate spending on research and development. She said the next 20 years would require Indian businesses to move beyond the creation of startups towards building enterprises that could scale, professionalise and endure.

Man tries to commit insurance fraud by setting car ablaze, blames fire on accident; arrested
Sep 22, 2026
Man tries to commit insurance fraud by setting car ablaze, blames fire on accident; arrested

Gondal Taluka police in Rajkot district have initiated proceedings against 26-year-old Deep Virdiya, who allegedly set his overturned car on fire to create the appearance of accidental damage and claim insurance money. Police said petrol was poured over the vehicle before it was ignited, while Virdiya allegedly told investigators the fire was caused by a short circuit.

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

Daily World Feed

Get yourself immersed in engaging topics right here. Daily World Feed is a multi-platform media, providing you latest breaking news straight from the industry.

Sign Up